{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:03:28Z","timestamp":1790337808273,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012576","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012576","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Materials Today Bio"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.mtbio.2026.103524","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:26:43Z","timestamp":1785770803000},"page":"103524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A multitargeting nanoparticle-based vaccine for enhanced anticancer immunotherapy in HER2-Positive breast cancer"],"prefix":"10.1016","volume":"40","author":[{"given":"Sen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintao","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6992-5526","authenticated-orcid":false,"given":"Haiyue","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taizhen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixiang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-4221","authenticated-orcid":false,"given":"Xiancai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mtbio.2026.103524_bib1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.mtbio.2026.103524_bib2","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.mtbio.2026.103524_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40291-013-0024-9","article-title":"HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies","volume":"17","author":"English","year":"2013","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.mtbio.2026.103524_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies \u2014 a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.mtbio.2026.103524_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab \u2014 mechanism of action and use in clinical practice","volume":"357","author":"Hudis Clifford","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mtbio.2026.103524_bib6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mtbio.2026.103524_bib7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jamaoncol.2020.7932","article-title":"Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-Positive advanced breast cancer: a phase 3 randomized clinical trial","volume":"7","author":"Rugo","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.mtbio.2026.103524_bib8","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/s41416-019-0619-y","article-title":"Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort","volume":"121","author":"Darlix","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mtbio.2026.103524_bib9","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.mtbio.2026.103524_bib10","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mtbio.2026.103524_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","article-title":"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients","volume":"6","author":"Nagata","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.mtbio.2026.103524_bib12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41467-019-14111-3","article-title":"Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade","volume":"11","author":"Bras\u00f3-Maristany","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103524_bib13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13058-021-01459-y","article-title":"Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions","volume":"23","author":"Ferraro","year":"2021","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.mtbio.2026.103524_bib14","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-08-1385","article-title":"NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations","volume":"68","author":"Serra","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.mtbio.2026.103524_bib15","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00262-010-0869-2","article-title":"Anti-HER2 vaccines: new prospects for breast cancer therapy","volume":"59","author":"Ladjemi","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.mtbio.2026.103524_bib16","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-Cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.mtbio.2026.103524_bib17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.mtbio.2026.103524_bib18","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.mtbio.2026.103524_bib19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.mtbio.2026.103524_bib20","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/annonc\/mdu211","article-title":"Final report of the phase I\/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients","volume":"25","author":"Mittendorf","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.mtbio.2026.103524_bib21","article-title":"Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy: Flamingo-01","volume":"43","author":"Patel","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mtbio.2026.103524_bib22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10549-020-05638-x","article-title":"Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence","volume":"181","author":"Brown","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.mtbio.2026.103524_bib23","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.2004.09.005","article-title":"Effect of dose on immune response in patients vaccinated with an HER-2\/neu intracellular domain Protein\u2014based vaccine","volume":"22","author":"Disis","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mtbio.2026.103524_bib24","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1200\/jco.2005.23.16_suppl.2520","article-title":"Phase I dose-escalation trial of a recombinant HER2 vaccine in patients with Stage II\/III HER2+ breast cancer","volume":"23","author":"Limentani","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mtbio.2026.103524_bib25","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0092-8674(01)00449-4","article-title":"Dendritic cells: Specialized and regulated antigen processing machines","volume":"106","author":"Mellman","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.mtbio.2026.103524_bib26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.mtbio.2026.103524_bib27","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.mtbio.2026.103524_bib28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.immuni.2010.10.008","article-title":"From vaccines to memory and back","volume":"33","author":"Sallusto","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.mtbio.2026.103524_bib29","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nri3488","article-title":"Applications of nanotechnology for immunology","volume":"13","author":"Smith","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.mtbio.2026.103524_bib30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mtbio.2026.103524_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115597","article-title":"Nanovaccines: a game changing approach in the fight against infectious diseases","volume":"167","author":"Priyanka","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.mtbio.2026.103524_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113889","article-title":"Nanotechnology-empowered vaccine delivery for enhancing CD8+ T cells-mediated cellular immunity","volume":"176","author":"Liu","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mtbio.2026.103524_bib33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/14760584.2019.1578216","article-title":"Immunological basis for enhanced immunity of nanoparticle vaccines","volume":"18","author":"Kelly","year":"2019","journal-title":"Expert Rev. Vaccine"},{"key":"10.1016\/j.mtbio.2026.103524_bib34","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.mtbio.2026.103524_bib35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jconrel.2017.08.009","article-title":"Lymph node targeting strategies to improve vaccination efficacy","volume":"267","author":"Jiang","year":"2017","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103524_bib36","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/nbt.3371","article-title":"In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity","volume":"33","author":"Lynn","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103524_bib37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41541-021-00330-7","article-title":"Protein-based antigen presentation platforms for nanoparticle vaccines","volume":"6","author":"Nguyen","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.mtbio.2026.103524_bib38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/vaccines12010030","article-title":"Nanoparticles and antiviral vaccines","volume":"12","author":"Liu","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.mtbio.2026.103524_bib39","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.immuni.2020.11.015","article-title":"Nanoparticle vaccines based on the Receptor binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 elicit robust protective immune responses","volume":"53","author":"Ma","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.mtbio.2026.103524_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009897","article-title":"Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection","volume":"17","author":"Geng","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.mtbio.2026.103524_bib41","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.abf6840","article-title":"Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice","volume":"371","author":"Cohen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.mtbio.2026.103524_bib42","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","article-title":"Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.mtbio.2026.103524_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113463","article-title":"Multimeric scaffolds displaying the HIV-1 envelope MPER induce MPER-Specific antibodies and cross-neutralizing antibodies when Co-Immunized with gp160 DNA","volume":"9","author":"Krebs","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.mtbio.2026.103524_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adr1777","article-title":"A modular metalloprotein in situ vaccine for cancer immunotherapy in mouse models of breast cancer","volume":"17","author":"Liu","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.mtbio.2026.103524_bib45","doi-asserted-by":"crossref","first-page":"6249","DOI":"10.1039\/C4TB00749B","article-title":"Presentation of HER2 epitopes using a filamentous plant virus-based vaccination platform","volume":"2","author":"Shukla","year":"2014","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.mtbio.2026.103524_bib46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.biomaterials.2016.12.030","article-title":"Plant viral nanoparticles-based HER2 vaccine: immune response influenced by differential transport, localization and cellular interactions of particulate carriers","volume":"121","author":"Shukla","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.mtbio.2026.103524_bib47","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1408749","article-title":"Virus-like particle display of HER2 induces potent anti-cancer responses","volume":"7","author":"Palladini","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.mtbio.2026.103524_bib48","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-Positive breast cancer","volume":"377","author":"Minckwitz","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mtbio.2026.103524_bib49","doi-asserted-by":"crossref","first-page":"26523","DOI":"10.1073\/pnas.1909653116","article-title":"Approaching infinite affinity through engineering of peptide\u2013protein interaction","volume":"116","author":"Keeble","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mtbio.2026.103524_bib50","doi-asserted-by":"crossref","first-page":"40437","DOI":"10.18632\/oncotarget.9624","article-title":"A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy","volume":"7","author":"Yan","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.mtbio.2026.103524_bib51","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41590-018-0292-y","article-title":"Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47\u2212mediated \u2018don\u2019t-eat-me\u2019 signal","volume":"20","author":"Liu","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.mtbio.2026.103524_bib52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12951-018-0380-z","article-title":"Small size fullerenol nanoparticles suppress lung metastasis of breast cancer cell by disrupting actin dynamics","volume":"16","author":"Qin","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.mtbio.2026.103524_bib53","doi-asserted-by":"crossref","first-page":"eadk2444","DOI":"10.1126\/sciadv.adk2444","article-title":"Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy","volume":"10","author":"Liu","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.mtbio.2026.103524_bib54","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/0952-7915(93)90056-X","article-title":"Antigen-presenting cell types","volume":"5","author":"Knight","year":"1993","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.mtbio.2026.103524_bib55","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.immunol.20.100301.064828","article-title":"Antigen presentation and T cell stimulation by dendritic cells","volume":"20","author":"Guermonprez","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.mtbio.2026.103524_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2023.113204","article-title":"3D culture boosting fullerenol nanoparticles to induce calreticulin exposure on MCF-7 cells for enhanced macrophage-mediated cell removal","volume":"224","author":"Liu","year":"2023","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.mtbio.2026.103524_bib57","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1021\/nn901478z","article-title":"[Gd@C82(OH)22]n nanoparticles induce dendritic cell maturation and activate Th1 immune responses","volume":"4","author":"Yang","year":"2010","journal-title":"ACS Nano"},{"key":"10.1016\/j.mtbio.2026.103524_bib58","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1002\/adma.201300583","article-title":"Morphologically Virus-like fullerenol nanoparticles act as the dual-functional nanoadjuvant for HIV-1 vaccine","volume":"25","author":"Xu","year":"2013","journal-title":"Adv. Mater."},{"key":"10.1016\/j.mtbio.2026.103524_bib59","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1002\/smll.201302825","article-title":"Polyhydroxylated metallofullerenols stimulate IL-1\u03b2 secretion of macrophage through TLRs\/MyD88\/NF-\u03baB pathway and NLRP3 inflammasome activation","volume":"10","author":"Chen","year":"2014","journal-title":"Small"},{"key":"10.1016\/j.mtbio.2026.103524_bib60","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz5466","article-title":"Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents","volume":"6","author":"Dormont","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.mtbio.2026.103524_bib61","doi-asserted-by":"crossref","first-page":"12127","DOI":"10.1021\/acsnano.2c12356","article-title":"Attenuating uncontrolled inflammation by radical trapping chiral polymer micelles","volume":"17","author":"Li","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.mtbio.2026.103524_bib62","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1021\/acs.nanolett.0c05039","article-title":"In situ transforming RNA nanovaccines from Polyethylenimine functionalized graphene oxide hydrogel for durable cancer immunotherapy","volume":"21","author":"Yin","year":"2021","journal-title":"Nano Lett."},{"key":"10.1016\/j.mtbio.2026.103524_bib63","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The Nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.mtbio.2026.103524_bib64","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.mtbio.2026.103524_bib65","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mtbio.2026.103524_bib66","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti\u2013PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.mtbio.2026.103524_bib67","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody\u2013mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mtbio.2026.103524_bib68","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ijc.25429","article-title":"Regulatory T cells in tumor immunity","volume":"127","author":"Nishikawa","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.mtbio.2026.103524_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01896","article-title":"CD8+ T-Cell response to HIV infection in the era of antiretroviral therapy","volume":"10","author":"Perdomo-Celis","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mtbio.2026.103524_bib70","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cellimm.2008.08.007","article-title":"Relationship between CD107a expression and cytotoxic activity","volume":"254","author":"Aktas","year":"2009","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.mtbio.2026.103524_bib71","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature12978","article-title":"Structure-based programming of lymph-node targeting in molecular vaccines","volume":"507","author":"Liu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.mtbio.2026.103524_bib72","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody\u2013drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.mtbio.2026.103524_bib73","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","article-title":"A HER2-Targeting antibody\u2013drug conjugate, Trastuzumab Deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model","volume":"17","author":"Iwata","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.mtbio.2026.103524_bib74","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-Positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mtbio.2026.103524_bib75","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature12202","article-title":"Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies","volume":"499","author":"Kanekiyo","year":"2013","journal-title":"Nature"}],"container-title":["Materials Today Bio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006426007696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006426007696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:40:19Z","timestamp":1790336419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590006426007696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":75,"alternative-id":["S2590006426007696"],"URL":"https:\/\/doi.org\/10.1016\/j.mtbio.2026.103524","relation":{},"ISSN":["2590-0064"],"issn-type":[{"value":"2590-0064","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multitargeting nanoparticle-based vaccine for enhanced anticancer immunotherapy in HER2-Positive breast cancer","name":"articletitle","label":"Article Title"},{"value":"Materials Today Bio","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mtbio.2026.103524","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103524"}}